You are viewing the site in preview mode

Skip to main content

Table 4 Shift tables of laboratory values based on notable/extended ranges

From: Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

  Baseline Worst post-baseline value
ALT (U/L) n (%) ≤ ULN, n (%) > ULN to ≤ 5 × ULN, n (%) > 5 × ULN, n (%) Notable range, n (%) Extended range, n (%)
≤ ULN 34 (64.2) 19 (55.9) 14 (41.2) 0 0 1 (2.9)
> ULN to ≤ 5 × ULN 19 (35.8) 0 17 (89.5) 0 2 (10.5) 0
Total 53 (100.0) 19 (35.8) 31 (58.5) 0 2 (3.8) 1 (1 .9)
AST (U/L) n (%) ≤ ULN, n (%) > ULN to ≤ 5 × ULN, n (%) > 5 × ULN, n (%) Notable range, n (%) Extended range, n (%)
≤ ULN 41 (77.4) 23 (56.1) 17 (41.5) 0 0 1 (2.4)
> ULN to ≤ 5 × ULN 12 (22.6) 0 12 (100.0) 0 0 0
Total 53 (100.0) 23 (43.4) 29 (54.7) 0 0 1 (1.9)
Serum creatinine n (%) ≤ ULN, n (%) Two consecutive > ULN, n (%) Notable range, n (%) Missing, n (%)  
≤ ULN 53 (100.0) 51 (96.2) 2 (3.8) 0 0  
Total 53 (100.0) 51 (96.2) 2 (3.8) 0 0  
Creatinine clearance n (%) ≥ 60, n (%) One value ≥ 40 to < 60, n (%) Notable range, n (%) One value < 40, n (%) Extended range, n (%)
≥ 60 50 (94.3) 45 (90.0) 2 (4.0) 1 (2.0) 2 (4.0) 0
≥ 40 to < 60 2 (3.8) 0 1 (50.0) 1 (50.0) 0 0
Missing 1 (1.9) 1 (100.0) 0 0 0 0
Total 53 (100.0) 46 (86.8) 3 (5.7) 2 (3.8) 2 (3.8) 0
Urinary protein/urinary creatinine ratio (mg/mmol) n (%) ≤ 113.1, n (%) One value > 113.1, n (%) Two values > 113.1, n (%) Notable range, n (%) Missing, n (%)
≤ 113.1 48 (90.6) 39 (81.3) 5 (10.4) 3 (6.3) 1 (2.1) 0
> 113.1 1 (1.9) 1 (100.0) 0 0 0 0
Missing 4 (7.5) 3 (75.0) 0 0 0 1 (25.0)
Total 53 (100.0) 43 (81.1) 5 (9.4) 3 (5.7) 1 (1.9) 1 (1.9)
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal